Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a
spectrum of burdensome dermatologic conditions. The US Food and Drug Administration …

Janus kinase (JAK) inhibitors are immunomodulatory agents with broad potential for use
within dermatology. However, the US Food and Drug Administration has recently placed …

Janus kinase inhibitors, also commonly referred to as JAK inhibitors, are a novel drug class
that target and block cytokine signaling mediated by the Janus kinase-signal transducer and …

The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway
is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti …

The class of medications known as Janus kinase inhibitors block cytokine-mediated
signaling via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) …

Background Janus kinase (JAK) inhibitors are emerging as a promising new treatment
modality for many inflammatory conditions. Objective Our aim was to systematically review …

Background Janus kinase (JAK) inhibitors have attracted attention for their role in treating
inflammatory disorders. This new class of biologics has the potential to significantly affect the …

Janus kinase family (JAKs) has recently attracted the attention of many researchers, and
several JAK inhibitor drugs have been developed targeting different members of the JAK …

Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic
drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised …

Janus kinase inhibition is promising in the treatment of RA, with already two oral drugs
marketed. New compounds are under investigation that are more selective for Janus kinase …